stockrowJazz Pharmaceuticals PLC (JAZZ) vs Kymera Therapeutics, Inc. (KYMR)
- Jazz Pharmaceuticals PLC JAZZ 237.51 +4.48%
- Kymera Therapeutics, Inc. KYMR 131.03 +2.27%
Jazz Pharmaceuticals PLC and Kymera Therapeutics, Inc. are both Biotechnology companies. Jazz Pharmaceuticals PLC is the larger, with a market value of $14.6B against $10.9B — 1.3× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Jazz Pharmaceuticals PLC trades at 62.6×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 13.5%. Jazz Pharmaceuticals PLC has the higher net margin (4.37% vs 0.00%) and the higher return on invested capital (3.86% vs −39.3%). Across the 18 metrics below, Jazz Pharmaceuticals PLC leads on 12 and Kymera Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | JAZZ | KYMR | Biotechnology median |
|---|---|---|---|
| Gross margin | 89.09% | 100.00% | 65.16% |
| Operating margin | 9.03% | 0.00% | 0.00% |
| Net margin | 4.37% | 0.00% | 0.00% |
| Free cash flow margin | 14.08% | 0.00% | 0.00% |
| Return on equity | 5.05% | (27.29%) | (50.12%) |
| Return on assets | 1.76% | (24.36%) | (45.60%) |
| Return on invested capital | 3.86% | (39.30%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack